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Abstract No data exist about the possibility that vertebral
fracture in PMR patients could be independent of steroid
therapy. For this reason, we aimed to investigate this topic
by a case cohort study with a 1-year follow-up for each
patient. We selected ten consecutive patients who experi-
enced vertebral fractures (VF-group) during the Wrst month
of 1-year follow-up period and without any other signiW-
cant associated condition. As a control group we studied
ten control patients, without vertebral fractures and with a
follow-up of 1 year, randomly selected among a larger
group of patients aVected by polymyalgia rheumatica. The
following data were analysed: eritrosedimention rate
(ESR), visual analogical scale score (VAS), methypredn-
isolone daily dosage. Each patient had been monthly evalu-
ated by the aforementioned clinical and laboratoristic
parameters during the 1-year follow-up period. The VF-
group resulted with a higher and statistically signiWcant
median corticosteroid 12-month total dosage [mean
3,480 mg (95%CI 2,805–3,030) vs. 2,760 mg (2,666.25–
3,247.5)]. The VF-group had statistically signiWcant higher
ESR and VAS AUC when compared to control group
(median ESR AUC, 484.75 vs. 288.25; P = 0.0001; median
VAS AUC, 70.75 vs. 43.5 P < 0.0001); ESR at the baseline
(cut-oV >80 mm) showed a speciWcity of 90% (95%CI 56–
100) and sensitivity of 70% (95%CI 35–93). VAS diVer-
ence from Wrst to second month (cut-oV ·3) showed a
speciWcity of 90% (95%CI 56–100) and sensitivity of 80%
(95% CI 44–97). Our results point out that vertebral frac-
ture might be predicted from commonly used laboratory
(ESR) and clinical (VAS) Wndings.
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Introduction
Polymyalgia Rheumatica (PMR) is an inXammatory condi-
tion of unknown cause that is characterized by an aching
and morning stiVness in the shoulder and pelvic girdles
other than the same kind of symptoms in the cervical
region.
Well-documented data are available from literature
about PMR and osteoporosis (1–3). In particular, the bene-
Wcial eVects of corticosteroid therapy in the treatment of
PMR may be oVset by the occurrence of corticosteroid-
related osteoporosis. So, several studies have addressed the
question of what dose of corticosteroids does not determine
deleterious eVect on bone density: the results of these stud-
ies prove that this dose is uncertain (4). On the other hand,
in our knowledge, there are no data about both the
frequency of vertebral fractures and related clinical features
in recently diagnosed PMR patients. Moreover, no data
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patients could be independent of steroid therapy.
For this reason, we aimed to investigate this last topic by
a case cohort study with a 1-year follow-up for each polym-
yalgia rheumatica patient who had experienced a vertebral
fracture within the Wrst month after the diagnosis.
Methods
We recruited ten consecutive patients who experienced
vertebral fractures (VF-group) between during a previous
2-year period (2006–2007 years) aVected by Wrst diagnosed
polymyalgia rheumatica, followed-up for 1 year, and with-
out any other signiWcant associated condition. All the frac-
tures were found out in acute symptomatic patients and had
occurred during the Wrst month after the diagnosis. As a
control group, we studied ten control patients, without ver-
tebral fractures and with a follow-up of 1 year, randomly
selected among a larger group of patients aVected by PMR.
Randomization was performed by links in order to obtain a
matched control group from some relevant variables (age,
BMI, gender, comorbidities and drug therapy).
All the patients were referred to the Rheumatologic out-
patient clinic of our Hospital trust, and all met the ACR cri-
teria for diagnosis of PMR (5, 6). Moreover, in each patient
of both groups PMR was diagnosed within 1 month from
the onset of symptoms.
Each patient underwent an X-ray at baseline, after
12 months, and when experienced an acute pain along
spine. The vertebral fractures were Wrst evaluated by X-ray
after an acute aching episode and conWrmed by axial
computerized tomography. We analysed the following data:
eritrosedimention rate (ESR), visual analogical scale score
(VAS) for pain assessment, methyprednisolone daily
dosage. Each patient had been monthly evaluated by the
aforementioned clinical and laboratoristic parameters dur-
ing the 1-year follow-up period. The two groups did not
meaningfully diVer for gender and age, neither there were
meaningful diVerences for steroidal dosing, ESR, VAS at
baseline. Moreover, the two groups did not diVer for per-
centage of patients overweight, hypertensive and diabetic
(Table 1). There were no signiWcant diVerences about drug
therapy (antidiabetic and antihypertensive) between the two
groups.
Statistical analysis
The results are presented as mean value § standard devia-
tion, median (interquartile range, as lower and upper quar-
tile) and percentages when appropriated. Unpaired t test
was used for comparison of means, Mann–Whitney U test
for comparison of medians, and Fisher’s exact test for
comparison of proportions. Area under curve (AUC) of
ESR and VAS, from baseline to 12 month control, was
computed for comparison between groups. Predictive val-
ues (post-test likelihood) with change, prevalence (pre-
test likelihood), sensitivity, speciWcity and likelihood
ratios with robust conWdence intervals were computed
from ESR and VAS values for prediction of vertebral
fractures. ROC plots and a ROC analysis were performed
to individuate best sensitivity and speciWcity cut-oV
points. A two-tailed alpha value of <0.05 was considered
to be signiWcant.
Results
Study population variables at baseline are shown in
Table 1.
Figures 1 and 2 show ESR and VAS trends of the VF-
group compared to the control one during 1-year follow-up.
Although the total amount of corticosteroids during the
Wrst 3 months of observation was not signiWcantly diVerent
between the two groups, the VF-group resulted with a
higher and statistically signiWcant (P = 0.0135) median cor-
ticosteroid 12-month total dosage [3,480 mg (2,805–3,030)
versus 2,760 mg (2,666.25–3,247.5)]. The VF-group had
statistically signiWcant higher ESR and VAS AUC when
compared to control group (median ESR AUC, 484.75 vs.
Table 1 Patient characteristics 
and variables at baseline: control 
group versus VF-group
Control group VF-group
No. 10 10
Gender (W/M) (5/5) (5/5)
Age (years) (mean § 1SD) 75.6 § 3.38 76.6 § 4.6
Prednisone dosage at baseline [median (lower-upper quartile)] 20 (20–25) 20 (20–25)
ESR at baseline [median (lower-upper quartile)] 77 (75–80) 86.5 (77.5–90)*
VAS at baseline [median (lower-upper quartile)] 10 (9–10) 10 (9–10)
No. of overweight patients 8 8
No. of hypertensive patients 4 4
No. of diabetic patients 1 2
VF-group patients with vertebral 
fractures, ESR eritrosedimention 
rate, VAS visual analogical scale 
score for pain assessment
* Statistically signiWcant 
comparison (P = 0.0403)123
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P < 0.0001);
ESR at the baseline (cut-oV >80 mm) showed a speciWc-
ity of 90% (95%CI 56–100) and sensitivity of 70% (95%CI
35–93). VAS diVerence from Wrst to second month (cut-oV
·3) showed a speciWcity of 90% (95%CI 56–100) and sen-
sitivity of 80% (95% CI 44–97).
Discussion
To our knowledge, this study is the Wrst that appraises the
incidence of vertebral fractures after the clinical onset of
the PMR. Our study deals with a case cohort study about 10
patients aVected by PMR with recent vertebral fractures
(VF-group) compared to 10 patients aVected by PMR with-
out vertebral fractures (NF-group). This is a pilot-study
considered both the design and the sample size. However,
this kind of design has allowed a strict selection of controls
closely matched to the cases for meaningful variables.
So, conclusions of our study and related hypothesis
could be suYciently strong to both elicit interest in scien-
tiWc community on this topic and consequently draw sound
clinical trials. Our results show that ESR was higher in
VF-group in comparison with controls (P = 0.0403) at
baseline. This Wnding suggests that subjects who will
develop vertebral fractures precociously after the onset of
PMR could belong to a subgroup of PMR subjects with a
higher probability of vertebral fractures independent from
steroid osteoporotic bone eVects.
In conclusion, our preliminary results point out that ver-
tebral fractures both represent a problem for patients
aVected by PMR, during the Wrst months after the onset of
symptoms, and could be predicted from commonly used
laboratory (ESR) and clinical (VAS) Wndings. Apart from
the importance to investigate pathophysiological mecha-
nisms, an eVort to understand the importance of our data
and the needs for a precocious instrumental evaluation for
osteoporosis, in this kind of patients, might be investigated
in future studies for better utilizing economic resources.
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Fig. 1 Box-wisker plot of ESR value year trend. Comparison between
VF (vertebral fracture) and control groups (median value: thick line,
1st and 3rd quartiles values, lower and upper box limits, min and max
values, lower and upper wisker limits)
Fig. 2 Box-wisker plot of VAS score year trend. Comparison between
VF (vertebral fracture) and control groups (median value: thick line,
1st and 3rd quartiles values, lower and upper box limits, min and max
values, lower and upper wisker limits)123
